Eur Rev Med Pharmacol Sci 2018; 22 (20): 6885-6895

DOI: 10.26355/eurrev_201810_16158

Application of minimal residual disease monitoring in pediatric patients with acute lymphoblastic leukemia

X. Qin, M.-Y. Zhang, W.-J. Liu

Pediatric Department, PI Research Unit of Children’s Blood and Tumor, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. liuwenjun200@gmail.com


Acute lymphoblastic leukemia (ALL) is a malignant neoplastic disease characterized by abnormal hyperplasia of immature lymphatic cells and has become the most common tumor in children. Although the efficacy of acute lymphoblastic leukemia in children was significantly increased with the adjustment of chemotherapy regimen, there were still a few patients who failed in treatment. The main reasons were relapse and drug resistance. Minimal residual disease (MRD) refers to a state in which there remain traces of leukemia cells that could not be detected using morphological methods in leukemia patients who are in complete remission after receiving the induction chemotherapy or bone marrow transplantation, which is considered to be the main cause of recurrence. The most commonly used methods for detection of MRD include flow cytometry (FCM), real-time quantitative polymerase chain reaction (RQ-PCR) and next-generation sequencing (NGS). MRD evaluation plays an important role in evaluating prognosis, predicting recurrence, guiding risk stratify and individualized therapy for children with ALL. In this paper, we reviewed the progresses in major detection methods for MRD that have been made in the clinical application of pediatric ALL.

Free PDF Download

To cite this article

X. Qin, M.-Y. Zhang, W.-J. Liu
Application of minimal residual disease monitoring in pediatric patients with acute lymphoblastic leukemia

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 20
Pages: 6885-6895
DOI: 10.26355/eurrev_201810_16158